PUFA-Diol Esters for Acne Prevention via Enzymatic Cleavage

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for acne often start after inflammatory lesions appear, and there is a need for a treatment that is proportional to the severity of acne and initiated early to prevent the development of inflammatory acne lesions.

Innovation Solution

Esters of alkane diol and polyunsaturated fatty acids, particularly omega 3 or 6, which are recognized and cleaved by bacterial lipase, releasing antibacterial diols and anti-inflammatory PUFAs to block the inflammatory cascade characteristic of acne, thereby preventing the progression of acne lesions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current acne treatments are initiated after inflammatory lesions appear, then treatment effectiveness is limited, but treatment complexity and side effects increase

Engineering Contradiction:
Improvetreatment effectivenessVSAvoidtreatment complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The ester compounds serve as preliminary protective agents that can be applied before inflammatory acne lesions develop. The esters remain stable on the skin surface until P. acnes colonization occurs, at which point bacterial lipase cleaves them to release antibacterial diols and anti-inflammatory PUFAs, preventing inflammation before it starts rather than treating established lesions

Inventive Principle:
Principle #10Preliminary action

2Object-affected harmful factors

If antibacterial agents are used to combat P. acnes colonization, then bacterial growth is inhibited, but inflammatory response may be exacerbated

Engineering Contradiction:
Improvebacterial colonizationVSAvoidinflammatory response
Core Design Contradiction:
Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The invention combines antibacterial diols and anti-inflammatory PUFAs into a single ester compound. When P. acnes lipase cleaves the ester, both components are released simultaneously: the diol component provides antibacterial activity against P. acnes while the PUFA component provides anti-inflammatory activity, thus treating both bacterial colonization and inflammation with one agent

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The ester bond acts as an intermediary mechanism that controls the release of both antibacterial and anti-inflammatory components. The ester remains intact during application and storage, then is specifically cleaved by P. acnes lipase at the site of colonization, providing targeted dual action only where needed rather than systemically affecting the entire skin

Inventive Principle:
Principle #24Intermediary (Mediator)

3Duration of action of stationary object

If treatments are applied frequently to prevent acne progression, then lesion development is blocked, but skin tolerance and user compliance may be reduced

Engineering Contradiction:
Improveprotection durationVSAvoiduser compliance
Core Design Contradiction:
Duration of action of stationary objectVSEase of operation

Solution Approach 1:

The ester compounds are designed to be self-activating through the P. acnes lipase enzyme that is naturally present when bacterial colonization occurs. The esters remain stable on the skin without degrading or causing irritation during normal wear, then automatically activate their antibacterial and anti-inflammatory functions in response to the specific enzymatic trigger from P. acnes, providing prolonged protection without requiring frequent reapplication or causing cumulative irritation

Inventive Principle:
Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The esters provide an adapted response to P. acnes colonization, inhibiting bacterial growth and inflammation from the first colonization, effectively blocking the evolution of acne lesions and preventing their worsening.

Implementation Method 1

esters of alkane diol and polyunsaturated fatty acid, which are recognized and cleaved by bacterial lipase, releasing antibacterial diols and anti-inflammatory PUFAs

Methodology Applied
Scientific EffectEnzyme: Enzyme

Implementation Method 2

esters of alkane diol and polyunsaturated fatty acid, which are recognized and cleaved by bacterial lipase

Methodology Applied
Scientific EffectHydrolysis: Hydrolysis

Data Source

PatentEP2379484B1Polyunsaturated fatty acid and diol ester as an Anti-acne agent
Publication Date: 2013.05.29 PIERRE FABRE DERMO COSMETIQUE SA
  • EP2379484B1 patent drawingFigure 1~2
  • EP2379484B1 patent drawingFigure 3
  • EP2379484B1 patent drawingFigure 4A~4C

AI summary

The present invention relates to compounds of the following formula (I): where n is an integer between 1 and 15, m is 0, 1, 2 or 3, and R is the hydrocarbon chain of a polyunsaturated fatty acid selected from among omega 3 and omega 6, as well as to pharmaceutical or cosmetic compositions containing same, to a method for preparing and using same, in particular for treating acne and seborrhoeic dermatitis.